Growth Hormone Secretagogue
GHRP-2 Research Peptide
GHRP-2 (Growth Hormone Releasing Peptide-2, CAS 158861-67-7) is a synthetic hexapeptide growth hormone secretagogue. It acts as a ghrelin receptor agonist and has been studied extensively in preclinical and early-phase clinical research for its effects on growth hormone release.
Compound identity
- Name
- GHRP-2
- Class
- Growth Hormone Secretagogue
- CAS number
- 158861-67-7
- Molecular formula
- C45H55N9O6
- Also known as
- Growth Hormone Releasing Peptide-2, KP-102, Pralmorelin
- Sequence
- D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2
Research context
GHRP-2 (pralmorelin, KP-102) has the sequence D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2 (CAS 158861-67-7, molecular formula C45H55N9O6, MW approximately 817.9 Da). It is a synthetic hexapeptide that acts as a selective agonist of the growth hormone secretagogue receptor (GHS-R1a), the same receptor activated by the endogenous hormone ghrelin. GHS-R1a is expressed in the pituitary, hypothalamus, and peripheral tissues. GHRP-2 stimulates growth hormone release both directly at the pituitary level and by stimulating hypothalamic somatotroph-regulatory circuits, making it a well-characterized research tool for studying the GHS-R1a signaling pathway.
GHRP-2 was characterized in preclinical models and progressed to clinical trial phases under the INN pralmorelin. Clinical studies examined its utility as a diagnostic agent for growth hormone deficiency — a stimulation test using GHRP-2 (1 μg/kg IV or 100 μg IM) with GH peak measurement at 30 and 60 minutes has been studied as a GH deficiency diagnostic. Research published in the Journal of Clinical Endocrinology & Metabolism and Endocrinology established pharmacokinetics, dose-response relationships, and receptor selectivity. GHRP-2 is a first-generation GHSR agonist; later compounds (including ipamorelin) were developed from this foundation with greater receptor selectivity.
As a research reagent, GHRP-2 is used in studies of GHS-R1a receptor pharmacology, growth hormone secretion dynamics, and the ghrelin signaling axis. DMV Research supplies GHRP-2 as a lyophilized powder with per-batch third-party Certificate of Analysis confirming identity by mass spectrometry and purity by HPLC to 99%+.
Frequently asked questions
What is GHRP-2?+
GHRP-2 (Growth Hormone Releasing Peptide-2, pralmorelin, KP-102) is a synthetic hexapeptide growth hormone secretagogue with the sequence D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2 (CAS 158861-67-7). It acts as an agonist at the ghrelin receptor (GHS-R1a) and is used in research to study growth hormone secretion pathways.
What is the difference between GHRP-2 and GHRP-6?+
GHRP-2 (CAS 158861-67-7) and GHRP-6 (CAS 87616-84-0) are both synthetic hexapeptide GHS-R1a agonists. GHRP-6 has the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2; GHRP-2 uses D-Ala at position 1 and D-2-naphthylalanine at position 2. Research literature suggests GHRP-2 produces stronger GH stimulation in some models with somewhat different co-secretion profiles.
What is the difference between GHRP-2 and Ipamorelin?+
Ipamorelin (CAS 170851-70-4) is a pentapeptide GHS-R1a agonist designed for higher receptor selectivity than GHRP-2. Published studies indicate ipamorelin has less co-stimulation of cortisol and prolactin compared to GHRP-2, making the two compounds useful for comparison research on secretagogue selectivity.
Is GHRP-2 approved for human use?+
No. GHRP-2 is not FDA-approved. As supplied by DMV Research, it is for in-vitro and pre-clinical laboratory research purposes only, not for human or veterinary use.
Research use only
All products are intended for laboratory and research use only (RUO) and are not for human consumption, ingestion, or any in-vivo use.
The statements on this page have not been evaluated by the FDA. GHRP-2 is not intended to diagnose, treat, cure, or prevent any disease. Content is provided for laboratory research reference only.